Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forum
February 6, 2020
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Dr. Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group and General Manager of Nicox Ophthalmics, Inc,, will present results from the NCX 470 Dolomites Phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 New Horizons Forum being held on February 7, 2020 in San Francisco, U.S.
NCX 470, a novel second generation nitric oxide (NO)-donating bimatoprost analog for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, is Nicox’s lead clinical development program. NCX 470 ophthalmic solution 0.065% demonstrated non-inferiority and statistical superiority to latanoprost ophthalmic solution 0.005%, the U.S. market leader in prostaglandin analog prescriptions, in the Dolomites trial, a U.S., multicenter, Phase 2 safety and efficacy clinical trial.
An End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) is scheduled in Q1 2020. The initiation of the first of two U.S. Phase 3 clinical trials (“Mont Blanc”) is expected by the end of Q2 2020.
The presentation will be available on Nicox’ website in the section “Presentations & Events”.